Credits Earned (2024) Crédits obtenus

Redeem Prepaid Membership

Tools for Practice Outils pour la pratique


#36 In atrial fibrillation: rate versus rhythm and how slow do you go?


CLINICAL QUESTION
QUESTION CLINIQUE
For patients with persistent atrial fibrillation (A Fib), how does medically attempting to restore/maintain sinus rhythm compare to rate control (and what should be the target heart rate)?


BOTTOM LINE
RÉSULTAT FINAL
Patients with persistent Afib are more likely to benefit from rate control than rhythm control. Targeting resting heart rate to <80 does not appear necessary. Regardless of the treatment strategy, anti-thrombotic therapy is central to management.



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
Rate versus rhythm: Two latest meta-analyses1,2 of 10-13 Randomized Controlled Trials (RCTs) comparing pharmacological rate versus rhythm control in 7,867 patients: 
  • Statistically significantly fewer hospitalizations:1 50.8% versus 58.3%, Number Needed to Treat (NNT)=14. 
  • No difference in individual composite of embolic events, or individual outcomes of death, stroke or systemic embolism, worsening heart failure, or bleeding.1,2 
  • Similar quality of life.2 
  • Less likely to be in sinus rhythm (example from largest RCT:3 35% versus 63%). 
Strict versus lenient rateRCT4 (614 patients, mean age 68 years, 66% male, 61% CHADS score 0-1, followed up to three years) compared strict rate control (resting heart rate target <80) or lenient rate control (resting heart rate target <110). Lenient rate control was not inferior to strict rate control in: 
  • Composite outcome of cardiovascular, bleed, and hospitalization (12.9% versus 14.9% [hazard ratio 0.84 (90% CI 0.58 to 1.21)].  
Context:   
  • Although historically it was thought attempting to restore sinus rhythm was advantageous, medications used to establish and maintain sinus rhythm have several risks.   
  • Even in patients with coexistent congestive heart failure and AFib, mortality and morbidity outcomes did not differ between rate and rhythm groups.5 
  • Canadian guidelines recommend:6 
    • Rate control for most patients; 
    • Select patients may benefit from rhythm control, e.g. highly symptomatic, quality of life impairment, multiple recurrences, arrhythmia-induced cardiomyopathy. 
  • Regardless of treatment strategy, antithrombotic therapy is central to AFib management.6 
updated jan 19 2018 by ricky


Latest Tools for Practice
Derniers outils pour la pratique

#370 Antibiotics or no antibiotics for acute diverticulitis, that is the question!

Do antibiotics change clinical outcomes for patients with acute uncomplicated diverticulitis?
Read Lire 0.25 credits available Crédits disponibles

#369 Remind me, do medications that target brain amyloid improve my dementia?

Are amyloid-targeting monoclonal antibodies safe and effective for mild cognitive impairment or Alzheimer’s dementia?
Read Lire 0.25 credits available Crédits disponibles

#368 Sodium Restriction in Heart Failure: Beneficial or pouring salt in the wound?

Does sodium restriction improve outcomes in patients with chronic heart failure?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • G. Michael Allan MD CCFP
  • Michael R Kolber MD CCFP MSc

1. Chatterjee S, Sardar P, Lichstein E, et al. PACE. 2013; 36:122-33.

2. Al-Khatib SM, Allen LaPointe NM, Chatterjee R, et al. Ann Intern Med. 2014; 160:760-73.

3. AFFIRM Investigators. N Engl J Med. 2002; 23:1825-33.

4. Van Gelder IC, Groenveld HF, Crijns HJ, et al. N Engl J Med. 2010; 362:1363-73.

5. Roy D, Talajic M, Nattel S, et al. N Engl J Med. 2008; 358:2667-77.

6. Verma A, Cairns JA, Mitchell LB, et al. Can J Cardiol. 2014; 30:1114-30.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.

Most recent review: 19/01/2018

By: Ricky D. Turgeon BSc(Pharm) ACPR PharmD

Comments:

Evidence Updated: New meta-analyses, updated guidelines; Bottom Line: Unchanged.

Learning at a glance
Yearly credits
Acquired ()
Your content by topic
Cardiology Dermatology Emergency
My Bookmarks